Should the FDA be the doctor of last resort?
作者信息
DeVita Vincent T
出版信息
Nat Clin Pract Oncol. 2005 Sep;2(9):423. doi: 10.1038/ncponc0292.
PMID:16264991
Abstract
摘要
相似文献
1
Should the FDA be the doctor of last resort?
Nat Clin Pract Oncol. 2005 Sep;2(9):423. doi: 10.1038/ncponc0292.
2
The ODAC chronicles--part 2. Statistics and clinical medicine in the USA: the triumph of science over art?
Expert Rev Anticancer Ther. 2004 Dec;4(6):941-4. doi: 10.1586/14737140.4.6.941.
3
Vision and will: the future of the FDA.
Oncologist. 2009 Apr;14(4):317-9. doi: 10.1634/theoncologist.2009-0053. Epub 2009 Apr 13.
4
New office and new leader aim to streamline FDA cancer drug review process.
J Natl Cancer Inst. 2005 May 18;97(10):708-9. doi: 10.1093/jnci/97.10.708.
5
Patient group seeks overhaul of FDA clinical trial system in court.
J Natl Cancer Inst. 2006 Sep 20;98(18):1268-70. doi: 10.1093/jnci/djj401.
6
Drug Development, Trial Design, and Endpoints in Oncology: Adapting to Rapidly Changing Science.
Clin Pharmacol Ther. 2017 May;101(5):572-574. doi: 10.1002/cpt.623. Epub 2017 Apr 4.
7
Managed care outlook. Oncologists: FDA needs to speed up approval of cancer-fighting drugs.
Manag Care. 2002 Jun;11(6):56.
8
Better prioritization may speed approval of adjuvant therapies in breast cancer.
J Natl Cancer Inst. 2008 Jun 18;100(12):842-4. doi: 10.1093/jnci/djn197. Epub 2008 Jun 10.
9
Accelerated approval and oncology drug development timelines.
J Clin Oncol. 2010 May 10;28(14):e226-7; author reply e228. doi: 10.1200/JCO.2009.26.2121. Epub 2010 Mar 1.
10
FDA starts moving on critical path, but initiative running out of steam.
J Natl Cancer Inst. 2007 Mar 21;99(6):426-7. doi: 10.1093/jnci/djk142.
引用本文的文献
1
Should terminally ill patients have the right to take drugs that pass phase I testing? Yes.
BMJ. 2007 Sep 8;335(7618):478. doi: 10.1136/bmj.39244.451192.AD.
Zotero 插件